Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II gemtuzumab ozogamicin trial in HLH, MAS, or relapsed/refractory solid tumors
2020-002428-36Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Sep 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemtuzumab ozogamicin in haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS) and Nonhematologic neoplasms (2 cohorts), sponsored by University of Birmingham. Primary endpoint: CD33-positive cell count. Status: unknown.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2020-002428-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002428-36.